Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2021 10:26 ET | Source: Galecto, Inc.

UPDATE: Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139

BOSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it will host...
March 23, 2021 08:30 ET | Source: Galecto, Inc.

Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139

BOSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it will host...
March 15, 2021 07:30 ET | Source: Galecto, Inc.

Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications

BOSTON, March 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that an...
February 09, 2021 08:00 ET | Source: Galecto, Inc.

Galecto to Present at Upcoming Investor Conferences

BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced Hans Schambye,...
January 08, 2021 08:00 ET | Source: Galecto, Inc.

Galecto Appoints Anne Prener to its Board of Directors

BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
January 04, 2021 16:01 ET | Source: Galecto, Inc.

Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
December 11, 2020 08:06 ET | Source: Galecto, Inc.

Galecto Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update

Successfully completed listing on US Nasdaq and raised over $150 million during recent IPO and preceding crossover round Funds to support preparations for potential EU conditional approval of GB0139...
November 30, 2020 08:00 ET | Source: Galecto, Inc.

Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF Biomarkers

The ERJ Paper shows major effects on biomarkers in IPF, linked to mortality and to fall in FVCThe inhaled GB0139 significantly reduced key plasma biomarkers from baseline vs placebo over 2 weeksGB0139...
November 23, 2020 16:01 ET | Source: Galecto, Inc.

Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors

Has extensive experience in pharma and biotech in U.S., Europe and globallyGalecto completed U.S. initial public offering and plans to initiate three Phase 2 trials in the coming months BOSTON and...
October 28, 2020 21:10 ET | Source: Galecto, Inc.

Galecto Announces Pricing of Initial Public Offering

BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the...